Interactome Biotherapeutics, an innovator in engineered small extracellular vesicle biotherapeutics for central nervous system diseases, has been accepted into the highly selective MassBio Drive Spring Cohort. This esteemed program connects early-stage biotech companies with crucial resources and mentorship from industry leaders in areas like regulatory strategy, business development, and investor relations.
Through this eight-week program, Interactome will also benefit from key partnerships with Henry Ford Innovations and Oxford University Innovation, whose cutting-edge technologies have significantly shaped the company’s advancements. With additional non-dilutive funding from Bristol Myers Squibb, Interactome Biotherapeutics is poised to gain momentum in its mission to deliver groundbreaking biotherapeutic solutions. CEO Adam Koster describes the opportunity as "a game-changer," accelerating their path to market and driving forward their innovative research.
To learn more read the full press release.
©2024 | All Rights Reserved | MichBio
Website powered by Neon One